Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | HEAD OF R&D | January 25, 2023 | January 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date January 25, 2023 · Filed January 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2033-01-25 | Direct | 30,000 |
Reported balance
After 2023-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-25 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2023 Filed Jan 27, 2023 21:02 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001104659-23-007510 · tm234565-1_4seq1.xml · derivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 219,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · derivative · entry 3 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 219,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 64,373 | $0.72 | $46,348.56 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · nonDerivative · entry 2 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,953 Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 219,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · nonDerivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:48 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 496,204 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002555 · form4-05182021_020547.xml · derivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,204 Underlying: Common Stock · 496,204 shares Expires 2031-04-01 F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:00 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 711,619 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001415889-21-001849 · form4-04022021_060425.xml · derivative · entry 3 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,619 Underlying: Common Stock · 711,619 shares Expires 2031-04-01 F3 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. The stock options vest and become exercisable over a four-year period, with one-fourth of the Issuer's shares of common stock underlying the options vesting on April 1, 2022, and with the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:00 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 44,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001849 · form4-04022021_060425.xml · derivative · entry 2 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,326 Underlying: Common Stock · 44,683 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan and will vest in full on December 1, 2021, subject to the Reporting Person's continued employment or other service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. F2 · derivative.expiration_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan and will vest in full on December 1, 2021, subject to the Reporting Person's continued employment or other service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:00 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantRestricted Stock Units · Derivative | 174,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001849 · form4-04022021_060425.xml · derivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,643 Underlying: Common Stock · 174,643 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan and will vest in full on December 1, 2021, subject to the Reporting Person's continued employment or other service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. F2 · derivative.expiration_date: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan and will vest in full on December 1, 2021, subject to the Reporting Person's continued employment or other service with the Issuer, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Promptly following vesting, and in any event on or prior to December 31, 2021, each restricted stock unit will be settled by delivery of one share of the Issuer's common stock to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.